Abstract：
UNASSIGNED: Cisplastin (CDDP) is a chemotherapeutic drug frequently used to manage a variety of cancers. However, its use is associated with hepatorenal toxicity resulting from elevated reactive oxygen species production.
UNASSIGNED: Herein, the hepatorenal protective effect of tert-butylhydroquinone (tBHQ) in cisplatin (CDDP)-treated rats was examined.
UNASSIGNED: Wistar male rats randomly divided into four groups: normal control, tBHQ, CDDP and tBHQ + CDDP received 50 mg/kg b.w./day of tBHQ orally for 14 days while 7 mg/kg b.w of CDDP was administered intraperitoneally on Day 8.
UNASSIGNED: CDDP increased serum biomarkers of hepatic (AST, ALP, ALT, GGT) and renal (creatinine, urea, uric acid, kidney injury molecule 1) function. The levels of nuclear factor erythroid-2-related factor 2 protein and the activities of superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase activities were decreased in liver and kidney. Also, CDDP increased hepatic and renal levels of NF-κB, TNFα, Bax and caspase-3 proteins and decreased hepatorenal levels of Bcl-2 protein in the liver and kidney. Pre-treatment with tBHQ prevented these negative effects.
UNASSIGNED: Pre-intervention with tBHQ attenuates hepatorenal toxicity of CDDP by dampening oxidative stress, inflammation and apoptosis.
UNASSIGNED: Herein, the hepatorenal protective effect of tert-butylhydroquinone (tBHQ) in cisplatin (CDDP)-treated rats was examined.
UNASSIGNED: Wistar male rats randomly divided into four groups: normal control, tBHQ, CDDP and tBHQ + CDDP received 50 mg/kg b.w./day of tBHQ orally for 14 days while 7 mg/kg b.w of CDDP was administered intraperitoneally on Day 8.
UNASSIGNED: CDDP increased serum biomarkers of hepatic (AST, ALP, ALT, GGT) and renal (creatinine, urea, uric acid, kidney injury molecule 1) function. The levels of nuclear factor erythroid-2-related factor 2 protein and the activities of superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase activities were decreased in liver and kidney. Also, CDDP increased hepatic and renal levels of NF-κB, TNFα, Bax and caspase-3 proteins and decreased hepatorenal levels of Bcl-2 protein in the liver and kidney. Pre-treatment with tBHQ prevented these negative effects.
UNASSIGNED: Pre-intervention with tBHQ attenuates hepatorenal toxicity of CDDP by dampening oxidative stress, inflammation and apoptosis.
摘要：
■顺铂酶(CDDP)是一种常用于治疗多种癌症的化疗药物。然而,它的使用与增加的活性氧产生引起的肝肾毒性有关。
■这里，研究了叔丁基对苯二酚（tBHQ）在顺铂（CDDP）治疗的大鼠中的肝肾保护作用。
■Wistar雄性大鼠随机分为四组:正常对照组,tBHQ,CDDP和tBHQ+CDDP口服接受50mg/kgb.w./天的tBHQ,持续14天,同时在第8天腹膜内施用7mg/kgb.w的CDDP。
■CDDP增加了肝脏的血清生物标志物（AST，ALP,ALT,GGT）和肾脏（肌酐，尿素,尿酸,肾损伤分子1)功能。核因子-2相关因子2蛋白水平和超氧化物歧化酶活性，过氧化氢酶,肝脏和肾脏的谷胱甘肽过氧化物酶和谷胱甘肽还原酶活性降低。此外，CDDP增加肝和肾NF-κB水平，TNFα,Bax和caspase-3蛋白以及肝脏和肾脏中Bcl-2蛋白的肝肾水平降低。用tBHQ预处理防止了这些负面影响。
■tBHQ预干预通过抑制氧化应激减弱CDDP的肝肾毒性，炎症和细胞凋亡。
■这里，研究了叔丁基对苯二酚（tBHQ）在顺铂（CDDP）治疗的大鼠中的肝肾保护作用。
■Wistar雄性大鼠随机分为四组:正常对照组,tBHQ,CDDP和tBHQ+CDDP口服接受50mg/kgb.w./天的tBHQ,持续14天,同时在第8天腹膜内施用7mg/kgb.w的CDDP。
■CDDP增加了肝脏的血清生物标志物（AST，ALP,ALT,GGT）和肾脏（肌酐，尿素,尿酸,肾损伤分子1)功能。核因子-2相关因子2蛋白水平和超氧化物歧化酶活性，过氧化氢酶,肝脏和肾脏的谷胱甘肽过氧化物酶和谷胱甘肽还原酶活性降低。此外，CDDP增加肝和肾NF-κB水平，TNFα,Bax和caspase-3蛋白以及肝脏和肾脏中Bcl-2蛋白的肝肾水平降低。用tBHQ预处理防止了这些负面影响。
■tBHQ预干预通过抑制氧化应激减弱CDDP的肝肾毒性，炎症和细胞凋亡。
